| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 56,869 | 117,058 | ||
| Marketable securities | 138,058 | 86,827 | ||
| Prepaid expenses | 1,375 | 1,766 | ||
| Other current assets | 1,997 | 1,577 | ||
| Total current assets | 198,299 | 207,228 | ||
| Operating lease right-of-use assets | 741 | 804 | ||
| Property, equipment and leasehold improvements, net | 213 | 239 | ||
| Other non-current assets | 103 | 68 | ||
| Finance lease right-of-use assets | 0 | 0 | ||
| Total assets | 199,356 | 208,339 | ||
| Accounts payable | 2,709 | 2,974 | ||
| Accrued expenses | 6,036 | 5,981 | ||
| Operating lease liabilities | 296 | 286 | ||
| Finance lease liabilities | 0 | 0 | ||
| Total current liabilities | 9,041 | 9,241 | ||
| Operating lease liabilities | 527 | 605 | ||
| Total liabilities | 9,568 | 9,846 | ||
| Common stock 0.001 par value 200,000,00 shares authorized at september 30, 2025 and december 31, 2024 and 128,215,113 and 93,602,631 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 128 | 122 | ||
| Additional paid-in capital | 511,118 | 508,033 | ||
| Accumulated other comprehensive income | 30 | 24 | ||
| Accumulated deficit | -321,488 | -309,686 | ||
| Total stockholders equity | 189,788 | 198,493 | ||
| Total liabilities and stockholders equity | 199,356 | 208,339 | ||
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)